News

Global Health EDCTP3 recorded a year of significant growth and impact in 2025, expanding its research portfolio, mobilising unprecedented partner investments and reinforcing its role as a leading global health partnership between Europe and Africa.

Global Health EDCTP3 is activating a €4 million emergency funding mechanism to support research activities addressing the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda.

The 13th EDCTP Forum will bring together researchers, policymakers, and funders to reinforce scientific collaboration, forge new partnerships and advance responses to shared health challenges.

New collaboration will support research on respiratory infections, infectious and non-communicable diseases, and strengthen international scientific cooperation.

Global Health EDCTP3 is investing €40 million to advance vaccines against dengue and chikungunya, two mosquito-borne viruses that are steadily expanding their reach.

Global Health EDCTP3 invests €21 million to develop new treatments, AI diagnostic tools, and vaccine strategies for diarrhoeal diseases as climate change makes outbreaks more frequent and harder to predict.

Global Health EDCTP3 has opened the calls for abstracts, scientific symposia and workshops for the EDCTP Forum 2027, one of the leading global health research events focused on infectious diseases in sub-Saharan Africa. The deadline for submissions is 2 September 2026 at 17:00 (Brussels time).

Applications are now open for the EDCTP Prizes 2027, recognising outstanding individuals and research teams from Africa and Europe for their achievements in global health research and innovation. Submissions are accepted until 2 September 2026.

Coartem® Baby, co-funded by EDCTP2 through the PAMAfrica consortium, closes a long-standing treatment gap for one of the most vulnerable patient groups.